We found that in SPRED2-deficient BC cells, ERα is also activated in a ligand-independent manner, most likely by the direct ERK1/2 phosphorylation of ERα on S118 since changing that site to alanine (S118A) abolished the response. The gene discussed is MAPK3; the disease is breast cancer.